Frontier Pharma Alzheimer’s Disease and Associated Indications Frontier Pharma Alzheimer’s Disease and Associated | Page 2

This has led to high levels of R&D investment over the past two decades, but clinical trial failure
rates within the indication are extremely high and treatment options remain limited. There are no
disease-modifying therapies for AD, and current approaches can only temporarily slow the
worsening of symptoms.
The report focuses on AD alongside four key associated behavioral and psychological indications:
anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and
contribute substantially to the disease burden.
Scope
Unmet need is extremely high in AD, with behavioral and psychological complications contributing
significantly to the disease burden
- What are the most important etiological risk factors and pathophysiological processes implicated
in AD?
- What is the current treatment algorithm?
- How common are anxiety, depression, psychosis and insomnia in AD?
Related reports by Radiant Insights:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
The AD pipeline is large and contains a very high proportion of first-in-class product innovation
- Which molecule types and molecular targets are most prominent across AD and its associated
indications?
- What are the connections, in terms of first-in-class innovation, between AD and its associated
indications?
- Which first-in-class targets are most promising?
- How does the level of first-in-class innovation differ between products in development for
anxiety, depression, psychosis and insomnia?
- How does first-in-class target diversity differ by stage of development and molecular target
class?
The deals landscape is active and dominated by G-protein coupled receptor (GPCR)-targeting
products
- Which indications attract the highest deal values?
- How has deal activity fluctuated over the past decade?
Follow Us: